Bayer, Janssen, M-S, AZ, Sanofi, Lundbeck, UCB fuel €170M EU-wide screening honeypot
This article was originally published in Scrip
Executive Summary
Seven pharmaceutical companies are taking part in a new European public-private drug discovery collaboration under which academia and industry will assemble a pool of hundreds of thousands of compounds as a way of attracting researchers with novel screening approaches and targets. A key part of the move is to develop compounds from academia that are designed to address "difficult and so far intractable" targets.